5,165 Deaths Reported Following COVID Vaccines: Latest VAERS Data

VAERS data released today showed 294,801 reports of adverse events following COVID vaccines, including 5,165 deaths and 25,359 serious injuries between Dec. 14, 2020 and May 28, 2021.

This week’s number of reported deaths among all age groups following COVID vaccines passed the 5,000 mark, up 759 from last week, according to data released today by the Centers for Disease Control and Prevention (CDC). The data comes directly from reports submitted to the Vaccine Adverse Event Reporting System (VAERS).

VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.

Every Friday, VAERS makes public all vaccine injury reports received as of a specified date, usually about a week prior to the release date. Today’s data show that between Dec. 14, 2020 and May 28, a total of 294,801 total adverse events were reported to VAERS, including 5,165 deaths — an increase of 759 over the previous week. There were 25,359 serious injuries reported, up 3,822 compared with last week.

Among 12- to 17-year-olds, there were 40 reports of heart inflammation and 16 cases of blood clotting disorders.

In the U.S., 292.1 million COVID vaccine doses had been administered as of May 28. This includes 123 million doses of Moderna’s vaccine, 158 million doses of Pfizer and 11 million doses of the Johnson & Johnson (J&J) COVID vaccine.

Of the 5,165 deaths reported as of May 28, 24% occurred within 48 hours of vaccination, 16% occurred within 24 hours and 38% occurred in people who became ill within 48 hours of being vaccinated.

This week’s data for 12- to 17-year-olds show:

This week’s total VAERS data, from Dec. 14, 2020, to May 28, 2021, for all age groups show:

Seven cases of heart inflammation reported in teen boys, new study shows

On June 4, The Defender reported seven boys between the ages of 14 and 19 in the U.S. reportedly developed chest pain and heart inflammation within four days of receiving a second dose of the Pfizer vaccine, according to a study published today in Pediatrics.

Heart imaging tests detected a rare type of heart muscle inflammation called myocarditis and pericarditis. None of the teens were critically ill but all were hospitalized.

Only one of the seven boys in the Pediatrics report displayed evidence of a possible previous COVID infection, and doctors determined none of them had a rare inflammatory condition linked with COVID or pre-existing conditions. It is possible myocarditis or pericarditis may be an additional rare adverse event related to systemic reactogenicity, but currently no causal association has been established between this vaccine and myopericarditis, the authors concluded.

A search in VAERS revealed 628 cases of myocarditis and pericarditis, among all age groups reported in the U.S following COVID vaccination between Dec.14, 2020 and May 28. Of the 628 cases reported, 392 cases were attributed to Pfizer, 206 cases to Moderna and 27 cases to J&J’s COVID vaccine.

Of the 628 total cases of heart inflammation, 40 cases occurred in children ages 12 to 17, all attributed to Pfizer’s COVID vaccine.

Israeli health officials find probable link between Pfizer vaccine and heart inflammation

As The Defender reported June 2, Israeli health officials found a probable link between Pfizer’s COVID vaccine — which the country has relied on almost exclusively in its vaccination drive — and dozens of cases of heart inflammation in young men following the second dose.

A study by Israeli health officials identified 275 cases of myocarditis in Israel between December 2020 and May 2021, including 148 cases that occurred within a month after vaccination. Of those 148 cases, 27 occurred after the first dose and 121 after the second dose. About half of the cases involved people with previous medical conditions.

Many of the cases were reported among men 16 to 30 years old, and most often in 16- to 19-year-olds. Most of the patients were discharged from the hospital in less than four days, and 95% of the cases were considered mild.